Does supplementing with Streptococcus salivarius K12 reduce the risk of upper respiratory tract infection? Original paper

In this 4-month randomized controlled trial in 112 young adults who were recruited from track-and-field sport centers in Italy, supplementing with the probiotic Streptococcus salivarius K12 did not affect the incidence of upper respiratory tract infection episodes or symptoms.